This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • External Eye Disease  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Jill S. Melicher Larson, MD; Lance K. Bergstrom, MD; J. Douglas Cameron, MD, MBA; Lori A. Erickson, MD; Terrence E. Grimm, MD

Arch Ophthalmol. 2007;125(7):985-986.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A 70-year-old man developed severe periorbital edema secondary to imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ). Imatinib mesylate is a tyrosine kinase inhibitor with a high degree of specificity for the BCR-ABL, KIT, and platelet-derived growth factor receptor β tyrosine kinases. It is thought that inhibition of platelet-derived growth factor receptor β results in disruption of fluid homeostasis in the eyelids, resulting in the development of periorbital edema.

Report of a Case

A 70-year-old man developed mild periorbital edema within 2 weeks of starting imatinib mesylate at 400 mg perday for treatment of BCR-ABL–positive chronicmyelogenous leukemia. Three months later, the patient developed accelerated-phase chronic myelogenous leukemia and his imatinib mesylate dose was increased to 600 mg per day. His periorbital edema became significantly worse and visually disrupting. The patient was . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION